Michael D. Geschwind MD PhD, FAAN, FANA
Professor of neurology and holds the Michael J. Homer Chair in Neurology in the UCSF School of Medicine
Join to View Full Profile
1651 4th Street, Suite 212San Francisco, CA 94158
Phone+1 415-353-2057
Fax+1 415-353-8292
Dr. Geschwind is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Geschwind is a neurologist in San Francisco, CA and is affiliated with multiple hospitals in the area, including UCSF Medical Center and Zuckerberg San Francisco General Hospital and Trauma Center. He received his medical degree from Albert Einstein College of Medicine and has been in practice 20 years. He is experienced in prion diseases, spinocerebellar ataxia, dementia, autoimmune neurology, and huntington's disesae.
Education & Training
Johns Hopkins UniversityResidency, Neurology, 1997 - 2000
UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1996 - 1997
Albert Einstein College of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2000 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
- Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
- TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease Start of enrollment: 2005 Sep 01
- CJD (Creutzfeldt-Jakob Disease) Quinacrine Study Start of enrollment: 2005 Apr 01
Publications & Presentations
PubMed
- PrP-facilitated cell signaling activates phospholipase Cɣ1 and triggers an Arc/Arg3.1 response in mouse and iPSC-derived human neurons.Daniel Ojeda-Juarez, Gail Funk, Daniel B McClatchy, Emily Richards, Alexander J Rajic
Stem Cell Reports. 2026-06-09 - 3 citationsPredictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3.Emilien Petit, Giulia Coarelli, David Morgan, Paulina Cunha, Hortense Hurmic
Brain. 2026-04-07 - 2 citationsStandardizing "Rapid": Applying the Clinical Dementia Rating to Define Rapidly Progressive Dementia.Nihal Satyadev, Yoav D Piura, Philip W Tipton, S Richard Dunham, John C Morris
Neurology. 2026-01-13
Journal Articles
- Neuroimaging in DementiaMichael D Geschwind, Fanny M Elahi, Christopher P Hess, Seminars in Neurology
Press Mentions
146th Annual Meeting of the American Neurological Association to Focus on Research and Development of Neurologic Disease TherapeuticsOctober 5th, 2021
Police Have Investigated Five Cases in Five Years of Dementia Sufferers Causing Fatal Injuries to OthersMay 24th, 2019
The Eyes Have ItNovember 20th, 2018
Grant Support
- Unraveling the earliest phases of vascular cognitive impairment and dementia using CADASIL--a monogenic form of small vessel cerebrovascular diseaseUNIVERSITY OF WISCONSIN-MADISON2021–2027
- Tracking longitudinal change in presymptomatic genetic prion disease (TLC-Pre-gPrD)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2025
- Predicting progression of human prion diseaseNIA2013–2018
- Early Diagnosis Of Human Prion DiseaseNational Institute On Aging2008–2011
- New Clinical Approaches To Creutzfeldt-Jakob DiseaseNational Institute On Aging2003–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
